MARKET

ESPR

ESPR

Esperion Thera
NASDAQ

Real-time Quotes | Nasdaq Last Sale

39.14
-0.22
-0.56%
After Hours: 39.14 0 0.00% 16:08 10/18 EDT
OPEN
39.23
PREV CLOSE
39.36
HIGH
39.78
LOW
38.47
VOLUME
244.74K
TURNOVER
--
52 WEEK HIGH
60.99
52 WEEK LOW
33.13
MARKET CAP
1.06B
P/E (TTM)
-12.8754
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of ESPR and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 13 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

EPS

ESPR News

  • Here's Why We're Not At All Concerned With Esperion Therapeutics's (NASDAQ:ESPR) Cash Burn Situation
  • Simply Wall St..10/04 13:34
  • Esperion Therapeutics: Low Risk And Primed For Substantial Growth
  • Seeking Alpha - Article.10/04 12:15
  • Stifel Nicolaus Maintains Buy on Esperion Therapeutics, Lowers Price Target to $70
  • Benzinga.09/18 12:04
  • Benzinga's Top Upgrades, Downgrades For September 16, 2019
  • Benzinga.09/16 14:17

More

Industry

Biotechnology & Medical Research
-1.17%
Pharmaceuticals & Medical Research
-0.94%

Hot Stocks

Name
Price
%Change

About ESPR

Esperion Therapeutics, Inc. is a lipid management company. The Company is a late-stage pharmaceutical company focused on developing and commercializing once-daily, oral therapies for the treatment of patients with elevated low-density lipoprotein cholesterol (LDL-C). With a targeted mechanism of action, bempedoic acid, the Company's lead product candidate, is an orally available, once-daily adenosine triphosphate (ATP)-citrate lyase (ACL) inhibitor that reduces cholesterol biosynthesis and lowers elevated levels of LDL-C by up-regulating the LDL receptor, but with reduced potential for muscle-related side effects. In addition to bempedoic acid as monotherapy, the Company is also developing bempedoic acid in a fixed dose combination with ezetimibe, an approved, non-statin, oral, LDL-C lowering therapy.
More

Webull offers Esperion Therapeutics Inc (ESPR) stock price, real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, stock news, and many more online research tools to help you make informed decisions.